<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856907</url>
  </required_header>
  <id_info>
    <org_study_id>RP13-009</org_study_id>
    <nct_id>NCT01856907</nct_id>
  </id_info>
  <brief_title>Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM</brief_title>
  <official_title>A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women With a Recent History of GDM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Woman's</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational diabetes mellitus (GDM) is defined as &quot;any degree of glucose intolerance with
      onset or first recognition during pregnancy.&quot; GDM is one of the most frequent metabolic
      disorders occurring during pregnancy. Approximately 7% of all pregnancies in the United
      States are complicated by gestational diabetes resulting in more than 200,000 cases annually.
      There is epidemiologic evidence associating GDM with insulin resistance, glucose intolerance,
      and type 2 diabetes (DM2). Among all the risk factors of diabetes mellitus, the experience of
      gestational diabetes is the strongest one. Systematic reviews of older studies conclude that
      35-60% women with gestational diabetes will develop type 2 diabetes at rates much greater
      than control groups who did not have glucose intolerance during pregnancy. Studies are needed
      for optimal postpartum and long-term health of women who have had GDM. Recent evidence
      suggests that incretin-based therapies may be useful for the treatment of DM2 because
      continuous administration of glucagon-like peptide 1 (GLP-1) produces substantial
      improvements in glucose control and ß-cell function in subjects with DM2. Inhibition of
      dipeptidyl peptidase-4 (DPP-4) increases the concentration of GLP-1 and may potentially delay
      disease progression in GDM considering the ß-cell function improvement in DM2 and ß-cell mass
      shown to increase in animal models. This study will examine if combination sitagliptin (a
      DPP-4 inhibitor)-plus metformin is more effective than metformin alone or placebo in
      improving metabolic parameters, specifically the impact on β-cell function, in prior GDM
      women with glucose abnormalities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gestational diabetes mellitus (GDM) is defined as &quot;any degree of glucose intolerance with
      onset or first recognition during pregnancy.&quot; GDM is one of the most frequent metabolic
      disorders occurring during pregnancy. Approximately 7% of all pregnancies in the United
      States are complicated by gestational diabetes resulting in more than 200,000 cases annually.
      There is epidemiologic evidence associating GDM with insulin resistance, glucose intolerance,
      and type 2 diabetes (DM2). Among all the risk factors of diabetes mellitus, the experience of
      gestational diabetes is the strongest one.

      Gestational diabetes is often the culmination of years of unrecognized and unmodified
      diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy.
      Systematic reviews of older studies conclude that 35-60% women with gestational diabetes will
      develop type 2 diabetes at rates much greater than control groups who did not have glucose
      intolerance during pregnancy. The higher rates were in studies of particular ethnic groups in
      the U.S. Presently, in the literature, there are described new, more efficient methods of
      diabetes prevention in groups with a high risk of this disorder, which involve both,
      lifestyle modification and pharmacological therapies. Lifestyle intervention was found to
      reduce the incidence of type 2 diabetes by 58% and metformin by 31% as compared with placebo.
      Studies are needed for optimal postpartum and long-term health of women who have had GDM.
      Considerable recent evidence suggests that incretin-based therapies may be useful for the
      treatment of DM2 because continuous administration of glucagon-like peptide 1 (GLP-1)
      produces substantial improvements in glucose control and ß-cell function in subjects with
      type 2 diabetes. Inhibition of dipeptidyl peptidase-4 (DPP-4) increases the concentration of
      GLP-1 and may potentially delay disease progression in GDM considering the ß-cell function
      improvement in DM2 and ß-cell mass shown to increase in animal models. This study will
      examine if combination sitagliptin-plus metformin is more effective than metformin alone or
      placebo in improving metabolic parameters, specifically the impact on β-cell function, in
      at-risk women with a recent history of GDM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2013</start_date>
  <completion_date type="Actual">September 28, 2017</completion_date>
  <primary_completion_date type="Actual">September 5, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization of Glucose Levels</measure>
    <time_frame>16 weeks</time_frame>
    <description>Normalization of glucose in patients with abnormal glucose levels is defined as a fasting glucose level of &lt;100 mg/dL and a 2-hour glucose level following a 75 gram oral glucose load of &lt;140 mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose</measure>
    <time_frame>16 weeks</time_frame>
    <description>Blood glucose in the fasting state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Glucose Level From the Oral Glucose Tolerance Test (OGTT)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The mean blood glucose is calculated by averaging the 4 blood glucose levels measure during a 75 gm oral glucose tolerance test . This involves summing the glucose levels measured at baseline, and 1/2 hour,1 hour and 2 hours after the glucose load and dividing by 4..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin Resistance</measure>
    <time_frame>16 weeks</time_frame>
    <description>Insulin resistance calculated from fasting glucose and insulin levels known as HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda Index of Insulin Sensitivity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Composite insulin sensitivity index calculated from from glucose and insulin levels obtained during the OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Disposition Index</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measure of pancreatic beta cell compensatory action known as IS-SI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride/HDL-Cholesterol Ratio</measure>
    <time_frame>16 weeks</time_frame>
    <description>The ratio of triglyceride to HDL cholesterol is used as an indirect measure of insulin resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measure of body weight corrected by height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measure of central fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-to-Height Ratio</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measure of central obesity adjusted for stature</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Liver Enzymes as Safety Measure</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of patients with no clinically significant changes in liver enzymes-measure of liver enzymes was a study safety endpoint</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Disorder of Glucose Regulation</condition>
  <arm_group>
    <arm_group_label>Sitagliptin-Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg/1000 mg twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 pill/BID for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin-Metformin</intervention_name>
    <description>Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication</description>
    <arm_group_label>Sitagliptin-Metformin</arm_group_label>
    <other_name>Janumet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Biguanide- insulin sensitizer</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>Will evaluate effect of lifestyle and diet only</description>
    <arm_group_label>Placebo pill</arm_group_label>
    <other_name>placebo control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females 18 years to 42 years of age who experienced gestational diabetes mellitus
             (GDM) during recent (within 12 months) pregnancy with prediabetic hyperglycemia
             determined by an oral glucose tolerance test (OGTT) with 75 g glucose postpartum.
             Study subjects will be inclusive of prior GDM women with impaired fasting glucose
             (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT) postpartum.

          -  Written consent for participation in the study

        Exclusion Criteria:

          -  Cholestasis during the past pregnancy

          -  Any hepatic diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of
             unknown etiology)

          -  Serum aspartate transaminase (AST) and/or alanine aminotransferase (ALT) level
             exceeding more than twice normal lab values

          -  Presence of hypersensitivity to sitagliptin or other DPP-4 inhibitor

          -  Current use of metformin, thiazolidinediones, GLP-1 receptor agonists, DPP-4
             inhibitors, or weight loss medications (prescription or over the counter [OTC])

          -  Prior use of medication to treat diabetes except gestational diabetes

          -  Use of drugs known to exacerbate glucose tolerance

          -  History of diabetes or prior use of medications to treat diabetes except GDM

          -  Creatinine clearance less than 60 ml/min

          -  Pregnancy planned during the coming two years

          -  Currently lactating

          -  Patient not willing to use adequate contraception during study period (unless
             sterilized)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Elkind-Hirsch, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Hospital, Louisiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha Paterson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Hospital, Louisiana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woman's Hospital</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <results_first_submitted>September 13, 2017</results_first_submitted>
  <results_first_submitted_qc>January 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2018</results_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's</investigator_affiliation>
    <investigator_full_name>Karen Elkind-Hirsch</investigator_full_name>
    <investigator_title>Director of Research</investigator_title>
  </responsible_party>
  <keyword>prediabetes</keyword>
  <keyword>impaired fasting/impaired glucose tolerance</keyword>
  <keyword>post gestational diabetes</keyword>
  <keyword>diabetes prevention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual data will only be shared with participant</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted from November 2014 to September 2017. Patients were recruited from the Woman's Hospital Metabolic Clinic</recruitment_details>
      <pre_assignment_details>. Patients were eligible for randomization if they had impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT) by OGTT. Patients with diabetes or normal glucose tolerance were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin-Metformin</title>
          <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
        </group>
        <group group_id="P2">
          <title>Placebo Pill</title>
          <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
        </group>
        <group group_id="P3">
          <title>Metformin</title>
          <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin-Metformin</title>
          <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
        </group>
        <group group_id="B2">
          <title>Placebo Pill</title>
          <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
        </group>
        <group group_id="B3">
          <title>Metformin</title>
          <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <description>Postpartum previous GDM females</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hyperglycemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Normalization of Glucose Levels</title>
        <description>Normalization of glucose in patients with abnormal glucose levels is defined as a fasting glucose level of &lt;100 mg/dL and a 2-hour glucose level following a 75 gram oral glucose load of &lt;140 mg/dL</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin-Metformin</title>
            <description>50 mg/1000 mg twice a day (BID)
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>1 pill/ twice a day (BID) for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>1000 mg twice a day (BID)
Metformin: Biguanide- insulin sensitizer</description>
          </group>
        </group_list>
        <measure>
          <title>Normalization of Glucose Levels</title>
          <description>Normalization of glucose in patients with abnormal glucose levels is defined as a fasting glucose level of &lt;100 mg/dL and a 2-hour glucose level following a 75 gram oral glucose load of &lt;140 mg/dL</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Study change from dysglycemia to normal glucose state</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.035</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Blood Glucose</title>
        <description>Blood glucose in the fasting state</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin-Metformin</title>
            <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Blood Glucose</title>
          <description>Blood glucose in the fasting state</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" spread="13"/>
                    <measurement group_id="O2" value="101" spread="13"/>
                    <measurement group_id="O3" value="93" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Subjects (SS)/ Treatment Group x repeated measures (visit) design</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Glucose Level From the Oral Glucose Tolerance Test (OGTT)</title>
        <description>The mean blood glucose is calculated by averaging the 4 blood glucose levels measure during a 75 gm oral glucose tolerance test . This involves summing the glucose levels measured at baseline, and 1/2 hour,1 hour and 2 hours after the glucose load and dividing by 4..</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin-Metformin</title>
            <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Glucose Level From the Oral Glucose Tolerance Test (OGTT)</title>
          <description>The mean blood glucose is calculated by averaging the 4 blood glucose levels measure during a 75 gm oral glucose tolerance test . This involves summing the glucose levels measured at baseline, and 1/2 hour,1 hour and 2 hours after the glucose load and dividing by 4..</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" spread="19"/>
                    <measurement group_id="O2" value="132" spread="17"/>
                    <measurement group_id="O3" value="143" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin Resistance</title>
        <description>Insulin resistance calculated from fasting glucose and insulin levels known as HOMA-IR</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin-Metformin</title>
            <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin Resistance</title>
          <description>Insulin resistance calculated from fasting glucose and insulin levels known as HOMA-IR</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.2"/>
                    <measurement group_id="O2" value="4.7" spread="3.8"/>
                    <measurement group_id="O3" value="2.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.047</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matsuda Index of Insulin Sensitivity</title>
        <description>Composite insulin sensitivity index calculated from from glucose and insulin levels obtained during the OGTT</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin-Metformin</title>
            <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Index of Insulin Sensitivity</title>
          <description>Composite insulin sensitivity index calculated from from glucose and insulin levels obtained during the OGTT</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="3.9"/>
                    <measurement group_id="O2" value="5.0" spread="4.9"/>
                    <measurement group_id="O3" value="5.2" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Disposition Index</title>
        <description>Measure of pancreatic beta cell compensatory action known as IS-SI</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin-Metformin</title>
            <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Disposition Index</title>
          <description>Measure of pancreatic beta cell compensatory action known as IS-SI</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427" spread="231"/>
                    <measurement group_id="O2" value="194" spread="93"/>
                    <measurement group_id="O3" value="170" spread="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride/HDL-Cholesterol Ratio</title>
        <description>The ratio of triglyceride to HDL cholesterol is used as an indirect measure of insulin resistance</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin-Metformin</title>
            <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride/HDL-Cholesterol Ratio</title>
          <description>The ratio of triglyceride to HDL cholesterol is used as an indirect measure of insulin resistance</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.4"/>
                    <measurement group_id="O2" value="4.5" spread="3.1"/>
                    <measurement group_id="O3" value="2.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Measure of body weight corrected by height</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin-Metformin</title>
            <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>Measure of body weight corrected by height</description>
          <units>kg/meters^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" spread="8"/>
                    <measurement group_id="O2" value="33.5" spread="9"/>
                    <measurement group_id="O3" value="33.6" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference</title>
        <description>Measure of central fat</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin-Metformin</title>
            <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference</title>
          <description>Measure of central fat</description>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" spread="14"/>
                    <measurement group_id="O2" value="93" spread="17"/>
                    <measurement group_id="O3" value="93" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist-to-Height Ratio</title>
        <description>Measure of central obesity adjusted for stature</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin-Metformin</title>
            <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
          </group>
        </group_list>
        <measure>
          <title>Waist-to-Height Ratio</title>
          <description>Measure of central obesity adjusted for stature</description>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".54" spread=".09"/>
                    <measurement group_id="O2" value=".57" spread=".1"/>
                    <measurement group_id="O3" value=".58" spread=".07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Factorial repeated measures ANOVA with Bonferroni contrast test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Liver Enzymes as Safety Measure</title>
        <description>Number of patients with no clinically significant changes in liver enzymes-measure of liver enzymes was a study safety endpoint</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin-Metformin</title>
            <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
          </group>
          <group group_id="O3">
            <title>Metformin</title>
            <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Enzymes as Safety Measure</title>
          <description>Number of patients with no clinically significant changes in liver enzymes-measure of liver enzymes was a study safety endpoint</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin-Metformin</title>
          <description>50 mg/1000 mg BID
Sitagliptin-Metformin: Experimental -DPP-4 inhibitor- oral medication</description>
        </group>
        <group group_id="E2">
          <title>Placebo Pill</title>
          <description>1 pill/BID for 16 weeks
Placebo pill: Will evaluate effect of lifestyle and diet only</description>
        </group>
        <group group_id="E3">
          <title>Metformin</title>
          <description>1000 mg BID
Metformin: Biguanide- insulin sensitizer</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Important limitations of the present study were the small number of patients in the treatment groups and the short interval (16 weeks) of drug treatment. Second, surrogate measures were used to estimate insulin sensitivity and secretion.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Karen Elkind-Hirsch</name_or_title>
      <organization>Woman's Hospital</organization>
      <phone>225-231-5278</phone>
      <email>karen.elkind-hirsch@womans.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

